Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy

• Status: Completed
• Trial end date: 2016-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine superiority of DP-R208 compare to each monotherapy in patient with hypertension and primary hypercholesterolemia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alvogen Korea
• Treatments: Candesartan; Candesartan cilexetil; Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Both man and woman who is over 19years old.

• Hypertension with primary cholesterolemia and satisfy the lab results that Mean msSBP is under 180mmHg and Mean msDBP is under 110mmHg and LDL-C is 250mg/DL or under and Triglycerides is under 400mg/dL

Exclusion Criteria:

• Therapeutic lifestylechange is not enought during the study period

• SBP difference is bigger than 20mmHg or DBP difference is bigger than 10mmHg at screening visit